Novo reports additional Phase II data for subcutaneous semaglutide in obesity

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) reported additional data from a Phase II trial in 957 obese patients without diabetes showing that a greater proportion of patients who

Read the full 279 word article

User Sign In